ZURICH, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare know-how firm that’s creating new improvements and disruptive diagnostic options that put individuals first, introduced that it has appointed Lars Birkmann as Chief Financial Officer (CFO) as of October 5, 2022, succeeding Adam O’Keeffe as advert interim CFO.
Mr. Birkmann, 44, has efficiently labored within the Swiss life sciences sector for over twenty years and has been concerned in all areas of finance from accounting, monetary management, treasury, and mergers and acquisitions. He will take over the CFO place at Achiko and be part of the Company’s Executive Committee. Prior to Achiko, Lars was the CFO at Ender Diagnostics AG (Bern) and earlier than that the CFO for Sensile Medical AG (Olten).
Lars has accomplished his research in Economics and Study in Law, and a level in Business from the Business School in Leipzig. He can be a federal knowledgeable in European and Swiss VAT legislation.
“We are excited to welcome Lars on board,” mentioned Mr. Steven Goh, CEO of Achiko AG. “It’s the start of a process to build an executive team and Board with Swiss representation and is a decisive step towards the Company’s final transformation into becoming a diagnostics and technology company.”
ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is creating disruptive diagnostic options that put individuals first. The Company’s lead product, AptameX™, is a fast, dependable Covid-19 check with a companion app, Teman Sehat™, providing a user-friendly digital well being passport. AptameX™ and Teman Sehat™ had been launched in Indonesia in mid-2021 and AptameX™ obtained the CE Mark within the European Union in May 2022.
The AptameX™ DNA aptamer checks may be quickly chemically synthesized, are cost-effective, simply scalable and have broad potential throughout a number of illness areas. Achiko goals to ship quick, correct and reasonably priced diagnostic testing for a spread of illnesses within the quickly evolving healthcare diagnostics area.
Headquartered in Zurich, Achiko has workplaces in Jakarta, and employees around the globe.
Media contacts:
ACHIKO AG
Investor Relations
E: [email protected]
Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: [email protected]
T: +41 44 266 67 67
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain okaynown and unokaynown dangers, uncertainties, and other factors, whelloch could trigger the actual outcomes, financial condition, performance, or achievements of Achiko AG to be materialsly different from any future outcomes, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is offering this communication as of this date and does not undertake to update any forward-looking statements compriseed herein as a end result of new information, future events or otherwise.
